title: Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer.
abstract: Results of continuous sunitinib, in combination with cetuximab and irinotecan every other week (SIC) for compassionate use in heavily pre-treated patients with mCRC are presented.
  
  
  METHODS
  Patients with mCRC resistant to oxaliplatin, irinotecan, 5-FU and cetuximab received SIC at two Danish oncologic departments. The regimen consisted of sunitinib given as a continuous-dosing in combination with cetuximab and irinotecan every other week (CetIri). The first six patients started with a daily oral dose of sunitinib of 12.5 mg. Subsequent patients started at a daily dose of 25 mg with the possibility to escalate to 37.5 mg.
  
  
  RESULTS
  Twenty-nine patients received SIC. No patient had an objective response, but 13 patients had subjective relief and 42% had stable disease. The median time to progression was 3.2 months and median overall survival was 7.4 months. Fatigue and leukopenia were the most frequently reported severe adverse event (18% grade 3 and 18% grade 3/4, respectively).
  
  
  CONCLUSIONS
  Sunitinib continuous-dosing with 25 mg/day can safely be combined with CetIri administered every other week.
authors.affiliation: Department of Oncology, Odense University Hospital, Odense, Denmark. Camilla.qvortrup@ouh.regionsyddanmark.dk
authors.forename: Camilla
authors.initials: C
authors.lastname: Qvortrup
authors.forename: Benny Vittrup
authors.initials: BV
authors.lastname: Jensen
authors.forename: Trine Lembrecht
authors.initials: TL
authors.lastname: Jorgensen
authors.forename: Dorte
authors.initials: D
authors.lastname: Nielsen
authors.forename: Jon Kroll
authors.initials: JK
authors.lastname: Bjerregaard
authors.forename: Per
authors.initials: P
authors.lastname: Pfeiffer
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D057176:Compassionate Use Trials; D003718:Denmark; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D000077146:Irinotecan; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D011758:Pyrroles / Q000008:administration & dosage*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D012189:Retrospective Studies; D000077210:Sunitinib; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007211:Indoles; D009944:Organoplatinum Compounds; D011758:Pyrroles; D000077150:Oxaliplatin; D000077146:Irinotecan; D020794:Receptor Protein-Tyrosine Kinases; D000068818:Cetuximab; D000077210:Sunitinib; D002166:Camptothecin